Date of publication: 2017-07-09 09:37
Dr. John C. Reed, ., . has been the Head of Roche Pharma Research & Early Development (Pred) at Roche Holding AG since April 7, 7568. He is an Adjunct professor at the University of California San Diego (UCSD) Department of Molecular Pathology, University of Florida, University of Central Florida, and in San Diego State University's Biology department.
I usually don’t decide on a recommendation until I’ve read the entire paper, although for poor quality papers, it isn’t always necessary to read everything.
As a speciality biopharma company we have two distinct ways that our proprietary platform can be used to mine biological insight to develop new products, and to test products rapidly and effectively such that late phase surprises and sets backs are minimised. By putting a ‘human in a lab,’ hVIVO is able to see disease in motion in order to get at the true biological levers of disease that are normally hidden from view. And through the very same ‘human lab’ approach, hVIVO is able to generate ‘disease in motion’ in order to test interventions against that disease.
Basophil Histamine Release Induced by Amoxicilloyl-poly-L-lysine Compared With Amoxicillin in Patients With IgE-Mediated Allergic Reactions to Amoxicillin
Arribas F, Falkencrone S, Sola J, Gomez-Serranillos MP, Laguna JJ, Montañez MI, Fernandez TD, Rodríguez D, Pineda F, Skov PS, Mayorga C, Torres MJ
[summary] [PDF full-Text] [Supplemental Materials]
Dr. Yusuke Nakamura discovered the APC (Familial Adenomatous Polyposis) tumor suppressor. Dr. Nakamura plays the leading role in the field of personalized medicine. He authored 6755 scientific articles.
I use annotations that I made in the PDF to start writing my review that way I never forget to mention something that occurred to me while reading the paper. Unless the journal uses a structured review format, I usually begin my review with a general statement of my understanding of the paper and what it claims, followed by a paragraph offering an overall assessment. Then I make specific comments on each section, listing the major questions or concerns. Depending on how much time I have, I sometimes also end with a section of minor comments. I may, for example, highlight an obvious typo or grammatical error, though I don’t pay a lot of attention to these, as it is the authors’ and copyeditors’ responsibility to ensure clear writing.
Contact Sensitization in Patients With Lower Leg Dermatitis, Chronic Venous Insufficiency, and/or Chronic Leg Ulcer: Assessment of the Clinical Relevance of Contact Allergens
Erfurt-Berge C, Mahler V
[summary] [PDF full-Text]
Professor Lisanti, ., . serves as the Director of the Manchester Breakthrough Breast Cancer Research Unit and holds the Muriel Edith Rickman Chair of Breast Oncology within the Institute of Cancer Sciences. He is also Professor of Cancer Biology and the new founding Director of the Manchester Centre for Cellular Metabolism (MCCM).
One of the key hurdles in today’s drug development paradigm is the difficulty of mapping the underlying mechanics of disease: to identify root causes and define the levers that affect development. This critical step typically takes more than ten years. But with our innovative human-based clinical approach, we can significantly accelerate this process.
To accelerate the dissemination of highly important scientific information, all accepted papers will be included directly to final paginated issues to be released to PubMed quickly and in their permanent form.
The reason causing the misconduct is the scientific assessment system. So we are trying to [change] that and hopefully with all this work, we can really help the scientists to do real research and publish quality papers.